Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Prioritising high-quality expedited COVID-19 vaccines
Small biotech companies were key to pushing forward their research on mRNA and associated technologies and adapting candidate vaccines to combat COVID-19. ICON was ideally placed to partner with these sponsors during the COVID-19 global pandemic.
Comprehensive due diligence
ICON was approached by a customer seeking our expertise in conducting drug asset evaluation consulting services. The client looked to evaluate pharmaceuticals suitable for in-licensing or co-development, placing particular emphasis on autoimmune diseases.
Enhancing strategic partnerships through streamlined EDC build processes
ICON collaborated with the trial sponsor to identify opportunities for improving specific processes related to electronic data capture (EDC) build for select studies.
Through a comprehensive SWOT analysis of a suite of studies, ICON identified areas for study build process improvements across the entire portfolio.
Through a comprehensive SWOT analysis of a suite of studies, ICON identified areas for study build process improvements across the entire portfolio.
Delivering high quality at low cost
We created a more sustainable organisational design for our partner, within their Data Management and Biostatistics functions, resulting in a 56% cost saving.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
Vendor consolidation with a top 10 pharma company
Read more about how we consolidated over 340 site management resources, from 70 vendors, across 30 countries resulting in a 91% reduction in client burden.
Data analytics enabled FSP solutions
In a multi-vendor FSP model for clinical monitoring, the client required the capability to aggregate and analyse data internally across all FSP providers.
Promoting growth and reducing turnover through rapid and efficient resource allocation
Due to unprecedented resourcing needs prompted by the COVID-19 pandemic, our large pharma partner required rapid and efficient resource allocation in an FSP model to reduce turnover and promote growth.
Virtual development model
A venture-backed biopharmaceutical company focused on therapies for rare diseases needed to accelerate late-stage development and commercialization. ICON provided technical and commercial assessments, collaborating closely to simplify the development program and develop ePROs and a novel biomarker approach for the rare disease asset.
Cardiac imaging and monitoring support for PAH trial
ICON provided a large pharma sponsor with consistent, accurate ECG and ECHO modality imaging, contributing to a breakthrough pulmonary arterial hypertension treatment.
Long-term benefits of FSP partnerships in biometrics
The sponsor sought out ICON’s data management resources for their support in several international and complex programs using our FSP model across several therapeutic areas: oncology, neurology, infectious disease, endocrinology, and nephrology.
Creating an industry-leading clinical operations risk management function
Discover how ICON's cross-functional collaboration led to to creation of an industry-leading clinical risk management platform.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.